Vitamin E Supplementation in Burn Patients

NCT ID: NCT01413620

Last Updated: 2021-09-21

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: PHASE1
• Study Classification: INTERVENTIONAL
• Study Start Date: 2011-08-31
• Study Completion Date: 2021-08-31

Brief Summary

Burned patients because of their increased oxidative stress have severely depleted vitamin E, which is a dietary antioxidant. Oxidative stress is responsible for much of the pathophysiology seen in burned patients, which leads to acute and chronic morbidity and mortality, in addition to a decrease in their quality of life. Oral vitamin E will be used to reverse the oxidative stress of burn injury and, in the process, decrease the secondary consequences of thermal trauma. This proposal will demonstrate the benefit of maintaining adequate vitamin E status.

Detailed Description

We have previously demonstrated that thermal injury depletes plasma vitamin E in pediatric burn patients. However, plasma changes reflect short-term vitamin E changes, whereas adipose tissue alpha-tocopherol concentrations reflect long-term vitamin E status. We reported last year that burn injury depleted vitamin E stores in adipose tissue in children by nearly half within one month following injury. Our long-term goal is to improve the quality of life of burn patients by preventing pulmonary and hepatic dysfunction that may occur from vitamin E depletion. The objectives of this application are to a) attenuate alpha-tocopherol depletion in burned patients by vitamin E supplementation, b) prevent or reverse oxidative stress in these patients, and c) collect pilot data on the effect of vitamin E supplementation on lung and liver function. Our central hypothesis is that the administration of high doses of alpha-tocopherol will prevent or restore levels of vitamin E in adipose tissue and reverse the oxidative state in burned patients. The rationale of the proposed studies is that in severe cases of vitamin E depletion, oxidative stress, fatty liver and lung dysfunction have all been reported in our patients. We will administer vitamin E supplements (300-1200 IU RRR-alpha-tocopherol) to burn subjects (n= 20 per group, 6-70 years, ≥20% total body surface burns) for fifteen days. The subjects will be randomly assigned into two groups: an early treatment group who will receive vitamin E for days 1-15 of the study, and a delayed treatment group who will receive vitamin E for days 16-30 of the study. Both groups will be studied for a total of thirty days. We will test the following aims: Aim 1: determine the degree that supplemental Vitamin E will attenuate alpha-tocopherol depletion. Aim 2: determine if supplemental Vitamin E reduces markers of oxidative stress in burned patients. Aim 3: collect preliminary data to establish the relationship between oxidative stress and pulmonary pathophysiology and fatty liver after burn injury. We will measure plasma and adipose tissue alpha-tocopherol and urinary and plasma markers of oxidative stress, prior to supplementation and then weekly. The proposed research is innovative because the oxidative stress of burn injury causes a severe depletion of an essential nutrient, vitamin E. Supplementation of vitamin E is a novel concept that may mitigate the complications of burns, including lung injury, fatty liver and peripheral neuropathy.

Conditions

Burn Injury

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

Vitamin E Treated

Group Type: EXPERIMENTAL

dl-alpha-tocopheryl acetate

Intervention Type: DRUG

Ages 6 months-1 year will receive 75 IU/day of dl-alpha-tocopheryl acetate, while ages 2-5 years will receive 150 IU/day. Ages 6-8 will receive 300 IU/day, while ages 9-13 will receive 600 IU/day, ages 14-17 will receive 800 IU/day, and ages 18-70 will receive 1200 IU/day. Vitamin E will be administered in a liquid or pill form. The dose of aqueous vitamin E (Aqueous Vitamin E Oral Drops, Silarx, No. 54838-0005-30, Spring Valley, NY) will be given orally. When/If the patient is able to eat independently, the dose of vitamin E may be given in a pill form (Novatol 5-57, No. 410217, Archer Daniels Midland Company, Decatur, IL). Depending on the subject's group, the supplement of vitamin E either will be given on days 1-15 of the study or days 16-30 of the study.

Untreated

Group Type: NO_INTERVENTION

No interventions assigned to this group

Interventions

dl-alpha-tocopheryl acetate

Ages 6 months-1 year will receive 75 IU/day of dl-alpha-tocopheryl acetate, while ages 2-5 years will receive 150 IU/day. Ages 6-8 will receive 300 IU/day, while ages 9-13 will receive 600 IU/day, ages 14-17 will receive 800 IU/day, and ages 18-70 will receive 1200 IU/day. Vitamin E will be administered in a liquid or pill form. The dose of aqueous vitamin E (Aqueous Vitamin E Oral Drops, Silarx, No. 54838-0005-30, Spring Valley, NY) will be given orally. When/If the patient is able to eat independently, the dose of vitamin E may be given in a pill form (Novatol 5-57, No. 410217, Archer Daniels Midland Company, Decatur, IL). Depending on the subject's group, the supplement of vitamin E either will be given on days 1-15 of the study or days 16-30 of the study.

Intervention Type: DRUG

Other Intervention Names

Vitamin E; Aqueous Vitamin E Oral Drops, Silarx, No. 54838-0005-30

Eligibility Criteria

Inclusion Criteria

• Age: 6 months - 85 years
• >20% TBSA burn

Exclusion Criteria

• Bleeding disorders
• Positive hepatitis or HIV screens
• Pregnancy (women)

• Minimum Eligible Age: 6 Months
• Maximum Eligible Age: 85 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University of Texas

OTHER

Sponsor Role: collaborator

Oregon State University

OTHER

Sponsor Role: collaborator

Shriners Hospitals for Children

OTHER

Sponsor Role: lead

Responsible Party

Jong O. Lee

Assistant Professor of Surgery and Faculty Surgeon

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Jong O Lee, MD

Role: PRINCIPAL_INVESTIGATOR

University of Texas Medical Branch, Shriners Hospitals for Children

Hal K Hawkins, MD, PhD

Role: STUDY_DIRECTOR

University of Texas Medical Branch, Shriners Hospitals for Children

Linda E Sousse, PhD, MBA

Role: STUDY_DIRECTOR

University of Texas Medical Branch, Shriners Hospitals for Children

Daniel L Traber, PhD

Role: STUDY_DIRECTOR

University of Texas Medical Branch, Shriners Hospitals for Children

Maret G Traber, PhD

Role: STUDY_DIRECTOR

Oregon State University

David N Herndon, M.D.

Role: STUDY_DIRECTOR

University of Texas Medical Branch, Shriners Hospitals for Children

Celeste C Finnerty, Ph.D.

Role: STUDY_DIRECTOR

University of Texas Medical Branch, Shriners Hospitals for Children

Locations

Shriners Hospitals for Children

Galveston, Texas, United States

Countries

United States

Other Identifiers

VitE2011

Identifier Type: -

Identifier Source: org_study_id